Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.49 |
| ▸ | CTRC | Q99895 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6553096 | 0.99 | F2 (0.48) | F2CTRCSLC6A2SLC6A4HTR3A | |
| SCHEMBL7496894 | 0.92 | SLC6A2 (0.50) | F2CTRCSLC6A2SLC6A4HTR3A | |
| Hydrochloric Acid SCHEMBL7496883 | 0.91 | SLC6A2 (0.49) | F2CTRCSLC6A2SLC6A4HTR3A | |
| SCHEMBL7451123 | 0.82 | F2 (0.47) | F2CTRCSLC6A2SLC6A4HTR3A | |
| SCHEMBL7451365 | 0.81 | F2 (0.67) | F2CTRCSLC6A2SLC6A4HTR3A | |
| SCHEMBL6553019 | 0.81 | F2 (0.73) | F2CTRCF10PRSS2 | |
| Acetic Acid SCHEMBL6552978 | 0.80 | F2 (0.69) | F2CTRCF10PRSS2 | |
| SCHEMBL6554465 | 0.80 | F2 (0.55) | F2CTRCF10PRSS2 | |
| Acetic Acid SCHEMBL7451219 | 0.79 | F2 (0.68) | F2CTRCF10PRSS2 | |
| Acetic Acid SCHEMBL7604487 | 0.79 | F2 (0.51) | F2CTRCF10PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883405-B1 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6414020-B2 | ANTIPROTEOLYTIC AMIDINO OR DERIVATIVE USEFUL FOR TREATING PENCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION | 3- DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20010025041-A1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-27 | — | — | US | disclosed |
| US-6281206-B1 | AMIDINO AND BENZAMIDINO COMPOUNDS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| US-6225302-B1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6133315-A | ADMINISTERING TO TREAT PANCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION IN A MAMMAL; COMPOUNDS SUCH AS 2-CHLOROBENZENESULFONIC ACID 3-(3-AMIDINOPROPOXY)-5-METHYLPHENYL ESTER HYDROCHLORIDE | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6034127-A | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025041-A1 | Amidino protease inhibitors | CTRL, PEPD, PRSS3 | F2 154/4885CTRC 25/4885SLC6A2 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.